Author Photo

Photo credit: Washington University in St. Louis

Book Cover Images

 

Long Bio

Michael S. Kinch, Ph.D. is Associate Vice Chancellor at Washington University in St Louis, where he helps lead entrepreneurship activities as well as research on innovation in biopharmaceutical research and development. Michael founded and leads the Centers for Research Innovation in Biotechnology (CRIB) and Drug Development (CDD).

Dr. Kinch's scientific background includes the development of new medicines for cancer, immunological and infectious diseases. His current work is primarily focused upon understanding the blend of science, medicine, business and law needed to support the development of new medicines. Prior to joining Washington University in July 2014, he led drug discovery at Yale University as Managing Director of the Yale Center for Molecular Discovery.

Before joining Yale in 2010, Dr. Kinch had served as Vice President of Research & Development and Chief Scientific Officer at Functional Genetics, Inc. in Gaithersburg, MD, where his research included investigation of Ebola virus, Dengue fever virus, pandemic influenza and other emerging infectious diseases. Preceding that, Dr. Kinch founded and led the Departments of Cancer Biology and In Vivo Biology at MedImmune, Inc.

Prior to MedImmune, Dr. Kinch served as a tenured Associate Professor of Cellular Pharmacology at Purdue University in West Lafayette, IN. He has published more than 100 manuscripts, been granted 15 US patents and published more than 100 pending patents.

His first book, A Prescription for Change (UNC Press, 2016), outlines a history of the biotechnology and pharmaceutical industries. Michael’s second book, Between Hope and Fear: A History of Vaccines (Pegasus Books, 2018) details a history of new cancer therapies based on immune oncology. His third book, The End of the Beginning, provides the history of new cancer therapies with the potential promise to eradicate this disease. Dr. Kinch was a postdoctoral fellow at the University of North Carolina at Chapel Hill, obtained a Ph.D. in Immunology from Duke University and a B.S. in Molecular Genetics from The Ohio State University.

Short Bio

A graduate of Ohio State and Duke, Michael Kinch was a cancer researcher at Purdue University before founding cancer research at MedImmune. Later guiding R&D for medicines to treat Ebola, pandemic influenza and bio-terrorism agents, Michael led drug discovery at Yale, where he also began studying the pharmaceutical industry. Since 2014, Michael has Centers for Research Innovation in Biotechnology and Drug Discovery at Washington University in St Louis. His books, A Prescription for Change, Between Hope and Fear and End of the Beginning convey a history of the personalities and breakthroughs behind life-saving vaccines and medicines.

Intro Bio

Michael S. Kinch grew up in Hamilton, Ohio; a setting made notorious in J.D. Vance's Hilbilly Elegy. After undergraduate studies at The Ohio State University, a Ph.D. in immunology at Duke University and postdoctoral studies at the University of North Carolina in Chapel Hill, he began an independent research program to study breast and prostate cancers at Purdue University. In 2001, Michael founded cancer research at MedImmune, an upstart biotechnology company destined to become an industry leader. He later led R&D to develop medicines to treat Ebola virus, pandemic influenza and other bio-terrorism agents. In 2010, Michael was recruited to lead drug discovery at Yale University, where he began to research the history of the pharmaceutical industry, which culminated in his first book, A Prescription for Change (UNC Press; 2016). Since 2014, Michael has been helping promote innovation and entrepreneurship at Washington University in St Louis, where he leads the Centers for Research Innovation in Biotechnology and Drug Discovery. His second book, Between Hope and Fear (Pegasus Books; 2018), conveys a history of vaccines and the rise of anti-vaccine movements. A third book, End of the Beginning (Pegasus Book; Spring 2019), provides an approachable overview of new breakthrough immune therapies for cancer that could presage the imminent eradication of the disease.